Related Experiment Videos
Soft cannabinoid analogues as potential anti-glaucoma agents.
A Buchwald1, H Derendorf, F Ji
1Center for Drug Discovery, College of Pharmacy, University of Florida, Gainesville, Florida, USA. abuchwald@kospharm.com
Die Pharmazie
|March 7, 2002
Summary
New cannabinoid derivatives lower intraocular pressure (IOP) effectively for glaucoma treatment. These soft drugs target local effects, avoiding systemic side effects and offering a safer therapeutic option.
Area of Science:
- Ophthalmology
- Pharmacology
- Medicinal Chemistry
Background:
- Cannabinoids can reduce intraocular pressure (IOP), a key factor in glaucoma.
- Current cannabinoid use for glaucoma is limited by significant systemic side effects.
- A retrometabolic/soft drug approach was employed to design novel cannabinoid derivatives.
Purpose of the Study:
- To design and synthesize novel cannabinoid derivatives with a local effect on IOP.
- To minimize or eliminate systemic side effects associated with cannabinoid use.
- To evaluate the efficacy and safety of these soft drug analogues for glaucoma management.
Main Methods:
- Synthesis of lead compounds and soft analogues using Pechmann condensation.
- Evaluation of intraocular pressure (IOP) lowering effects of synthesized compounds.
- Pharmacokinetic/pharmacodynamic (PK/PD) modeling to describe experimental data.
Main Results:
- All successfully synthesized compounds demonstrated an IOP-lowering effect.
- The common metabolite of the soft analogues was found to be inactive.
- Soft analogue 8 showed prolonged topical effect but no systemic activity, with its metabolite being inactive.
- PK/PD modeling successfully described preliminary intravenous experimental data.
Conclusions:
- Designed soft cannabinoid analogues are effective for topical glaucoma control.
- These analogues minimize systemic side effects, offering a safer alternative.
- The retrometabolic/soft drug strategy is promising for developing novel glaucoma therapeutics.